Form 4: Addex Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Jason Raleigh Nunn, a Director of Addex Therapeutics Ltd., reported multiple transactions in common stock on September 2, 2026.
Summary
- Disposition to the issuer: disposed of 219,561 Common Stock on September 2, 2026 (Direct).
- Grant/award: acquired 219,561 Common Stock on September 2, 2026; holds 219,561 after (Direct).
- Disposition to the issuer: disposed of 50,000 Stock-option (Right to Buy) on September 2, 2026 (Direct).
- Grant/award: acquired 50,000 Stock-option (Right to Buy) on September 2, 2026; holds 50,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jason Raleigh Nunn — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-02 | Disposition to the issuer | Common Stock | 219,561 | — | — | 0 |
| 2026-09-02 | Grant/award | Common Stock | 219,561 | — | — | 219,561 |
| 2026-09-02 | Disposition to the issuer | Stock-option (Right to Buy) | 50,000 | — | — | 0 |
| 2026-09-02 | Grant/award | Stock-option (Right to Buy) | 50,000 | — | — | 50,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-02 | Disposition to the issuer (219,561 shares) |
| 2026-09-02 | Grant/award (219,561 shares) |
| 2026-09-02 | Disposition to the issuer (50,000 shares) |
| 2026-09-02 | Grant/award (50,000 shares) |
Keywords
insider transaction, Form 4, ADXN, Addex Therapeutics Ltd., neutral, Jason Raleigh Nunn
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.